Thursday, Soligenix, Inc. (SNGX) announced that the FDA has given orphan drug status for the active component in SuVax, a subunit protein vaccine created to prevent and provide post-exposure prophylaxis against Sudan ebolavirus infection.
Oreola Donini, chief scientific officer at Soligenix, pointed out the vaccines' 100 protection rate in studies on non-human primates. SuVax has also demonstrated stability for a minimum of two years at temperatures as high as 40 degrees Celsius.
If approved by the FDA, this designation would secure SuVax with seven years of exclusive market rights in the United States.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.